Anthrax - Pipeline Review, H2 2017

Date: July 18, 2017
Pages: 142
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A5A46C43DC2EN
Leaflet:

Download PDF Leaflet

Anthrax - Pipeline Review, H2 2017
Anthrax - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Pipeline Review, H2 2017, provides an overview of the Anthrax (Infectious Disease) pipeline landscape.

Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anthrax - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 24 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anthrax (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Anthrax (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anthrax (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anthrax (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anthrax (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Anthrax - Overview
Anthrax - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Anthrax - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anthrax - Companies Involved in Therapeutics Development
Altimmune Inc
Aphios Corp
Aradigm Corp
Companhia Industrial Produtora de Antibioticos SA
ContraFect Corp
Crestone Inc
Dynavax Technologies Corp
Emergent BioSolutions Inc
GlaxoSmithKline Plc
Green Cross Corp
Grifols SA
Hawaii Biotech Inc
iBio Inc
Merck & Co Inc
Microbiotix Inc
NanoBio Corp
PaxVax Inc
Pfenex Inc
Protein Potential LLC
ProThera Biologics Inc
Soligenix Inc
Syntiron LLC
Tetraphase Pharmaceuticals Inc
VLP Biotech Inc
Anthrax - Drug Profiles
anthrax (virus like particles) vaccine - Drug Profile
anthrax + plague vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax - Drug Profile
ARD-3100 - Drug Profile
AV-7909 - Drug Profile
BDM-I - Drug Profile
CF-306 - Drug Profile
CF-307 - Drug Profile
CF-308 - Drug Profile
ciprofloxacin hydrochloride - Drug Profile
CPN-1311 - Drug Profile
DPX-Anthrax - Drug Profile
DV-230 - Drug Profile
epimerox - Drug Profile
EV-035 - Drug Profile
GC-1109 - Drug Profile
gepotidacin mesylate - Drug Profile
GREANX - Drug Profile
KKL-35 - Drug Profile
Marinus - Drug Profile
Monoclonal Antibody for Anthrax - Drug Profile
Monoclonal Antibody for Anthrax - Drug Profile
Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile
Nasoshield - Drug Profile
PBI-220 - Drug Profile
Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile
Protein to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile
Px-563L - Drug Profile
Px-563L Second Generation - Drug Profile
raxibacumab - Drug Profile
Recombinant Proteins for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and Anthrax - Drug Profile
RiVax + SGX-204 - Drug Profile
rPA-01 - Drug Profile
RPA-563 - Drug Profile
Small Molecules for Bacterial Infections, Skin Infections and Bone Disorders - Drug Profile
Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax - Drug Profile
Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile
Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile
Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile
solithromycin - Drug Profile
SparVax - Drug Profile
TP-271 - Drug Profile
Anthrax - Dormant Projects
Anthrax - Discontinued Products
Anthrax - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Anthrax, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Anthrax - Pipeline by Altimmune Inc, H2 2017
Anthrax - Pipeline by Aphios Corp, H2 2017
Anthrax - Pipeline by Aradigm Corp, H2 2017
Anthrax - Pipeline by Companhia Industrial Produtora de Antibioticos SA, H2 2017
Anthrax - Pipeline by ContraFect Corp, H2 2017
Anthrax - Pipeline by Crestone Inc, H2 2017
Anthrax - Pipeline by Dynavax Technologies Corp, H2 2017
Anthrax - Pipeline by Emergent BioSolutions Inc, H2 2017
Anthrax - Pipeline by GlaxoSmithKline Plc, H2 2017
Anthrax - Pipeline by Green Cross Corp, H2 2017
Anthrax - Pipeline by Grifols SA, H2 2017
Anthrax - Pipeline by Hawaii Biotech Inc, H2 2017
Anthrax - Pipeline by iBio Inc, H2 2017
Anthrax - Pipeline by Merck & Co Inc, H2 2017
Anthrax - Pipeline by Microbiotix Inc, H2 2017
Anthrax - Pipeline by NanoBio Corp, H2 2017
Anthrax - Pipeline by PaxVax Inc, H2 2017
Anthrax - Pipeline by Pfenex Inc, H2 2017
Anthrax - Pipeline by Protein Potential LLC, H2 2017
Anthrax - Pipeline by ProThera Biologics Inc, H2 2017
Anthrax - Pipeline by Soligenix Inc, H2 2017
Anthrax - Pipeline by Syntiron LLC, H2 2017
Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017
Anthrax - Pipeline by VLP Biotech Inc, H2 2017
Anthrax - Dormant Projects, H2 2017
Anthrax - Dormant Projects, H2 2017 (Contd..1), H2 2017
Anthrax - Dormant Projects, H2 2017 (Contd..2), H2 2017
Anthrax - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Anthrax, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017
Skip to top


Anthrax - Pipeline Review, H1 2017 US$ 2,000.00 Feb, 2017 · 142 pages
Microbiotix, Inc. - Product Pipeline Review - 2016 US$ 1,500.00 Mar, 2016 · 52 pages
Hawaii Biotech, Inc. - Product Pipeline Review - 2015 US$ 1,500.00 Sep, 2015 · 24 pages
PaxVax - Product Pipeline Review - 2014 US$ 1,500.00 Sep, 2014 · 27 pages
Syntiron LLC - Product Pipeline Review - 2015 US$ 1,500.00 Jul, 2015 · 23 pages

Ask Your Question

Anthrax - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: